ALERT! The U.S. Election Could Spark a Run on Weed Stocks

US federal cannabis legalization is being pushed by a major US Presidential candidate, which could be great news for Canopy Growth Corp. (TSX:WEED)(NYSE:CGC).

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

The 2015 Canadian federal election sparked a massive run for cannabis stocks that made many fortunes. In late 2019 I discussed why the most recent federal election would not lead to any consequential changes in the near term for the industry.

The handling of legal cannabis has left a lot to be desired in Canada, as supply issues and a lack of retail availability on the ground have driven consumers back into the arms of the black market.

Infor Financial Group CEO Neil Selfe said in 2019 that Canada missed its chance to be a global leader in the emerging sector.

Canopy Growth (TSX:WEED)(NYSE:CGC) stock has dropped 54% year over year as of mid-afternoon trading on February 5.

Shares received a shot in the arm recently after Bank of Montreal analysts raised its price target. BMO cited reports that Canopy was outselling other product lines at the retail level.

This is especially encouraging news after “Cannabis 2.0,” which included the legalization of edibles and vape pens in late 2019.

There is another development that could spark a massive run for Canopy Growth over the next year  — one that investors need to keep an eye on.

Cannabis and the 2020 U.S. election

Investors saw firsthand the explosive impacts an election can have on a young industry like cannabis. The prospect of federal legalization in the United States has been a dream for cannabis boosters for years.

Leading democrats and republicans have dragged their feet on the issue, preferring instead to punt the issue to states. This could change in the 2020 election, however.

It goes without saying that there’s incredible uncertainty as we look ahead to November 2020. The Democratic primary kicked off this week with the controversial Iowa caucuses.

Astoundingly, the results have yet to be fully unveiled. As it stands today, Democratic candidates Pete Buttigieg and Bernie Sanders appear to be contending for the most delegates.

The next primary takes place in New Hampshire next week, where Bernie Sanders holds a comfortable lead in the polls.

Sanders has now climbed above his competition, according to odds makers. The race will grow even more interesting with the entrance of Michael Bloomberg after the first four primaries.

The former New York mayor has seemingly limitless cash reserves that he has vowed to spend liberally in a bid to win the nomination.

Though it’s still early, Sanders looks like the front runner, which should make cannabis enthusiasts happy. “We will end the destructive war on drugs,” Sanders said recently at a rally in Cedar Rapids.

“On my first day in office through executive order we will legalize marijuana in every state in this country.” Michael Bloomberg, on the other hand, is vehemently opposed to legalization.

What does this mean for cannabis stocks?

We will have a long primary to sit through before a democratic nominee is chosen. Even a small shot at federal legalization is reason for excitement if you’re betting on Canopy Growth.

The company has established a bridgehead into the massive U.S. market with its conditional acquisition of Acreage Holdings.

It also has its multi-billion partnership with Constellation Brands to lean on. Federal legalization in the U.S. would be huge for Canopy Growth this decade, and so Cannabis investors will want to keep their eyes on this election.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool recommends Constellation Brands.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »